OncoTect for Taxanes in Advanced Breast Cancer

About Aida Oncology

Aida Oncology is a private, pre-revenue diagnostics company leveraging machine learning on RNA expression data to predict chemotherapy efficacy, starting with taxanes in breast cancer. The company has presented multiple clinical validation studies at major conferences (ESMO 2025, SABCS) for its multigene signatures. Its business model targets the large, underserved market of chemotherapy selection, aiming to reduce ineffective treatments and improve patient outcomes.

Therapeutic Areas